Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma

Area of Science:

• Oncology
• Cancer Stem Cell Biology
• Prostate Cancer Research

Background:

• The cancer stem cell hypothesis posits that residual tumor-initiating cells cause relapse after conventional prostate cancer therapy.
• Identifying differences between bulk tumor cells and cancer stem cells is crucial for effective treatment strategies.
• The PTEN/PI3K/AKT pathway is implicated in maintaining prostate cancer stem cell populations.

Purpose of the Study:

• To investigate the efficacy of targeting the PI3K/mTOR pathway in prostate cancer.
• To evaluate the combination therapy of a PI3K/mTOR inhibitor with chemotherapy for prostate cancer treatment.
• To determine if PTEN mutations can predict response to dual therapy.

Main Methods:

• Utilized the dual PI3K/mTOR inhibitor NVP-BEZ235 to target prostate cancer progenitor cells.
• Administered NVP-BEZ235 in combination with the chemotherapeutic drug Taxotere.
• Assessed tumor eradication in a prostate cancer xenograft model.
• Analyzed PTEN mutations to correlate with therapeutic response.

Main Results:

• Inhibition of PI3K activity with NVP-BEZ235 reduced the population of CD133(+)/CD44(+) prostate cancer progenitor cells in vivo.
• Combination therapy of NVP-BEZ235 and Taxotere demonstrated superior tumor eradication compared to monotherapy.
• The dual therapy led to the expansion of cancer progenitors with a specific PTEN E91D mutation.

Conclusions:

• Targeting PI3K/mTOR signaling, in combination with chemotherapy, offers a promising strategy for prostate cancer treatment.
• The combination of NVP-BEZ235 and Taxotere effectively eliminates both bulk tumor cells and prostate cancer progenitor populations.
• Analysis of PTEN mutations, particularly the E91D variant, may serve as a predictive biomarker for therapeutic response to this dual therapy.